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Summary
Background Pyoderma gangrenosum (PG) is a rare, neutrophilic, ulcerative skin
disease that is difficult to treat, especially when unresponsive to steroids.
Objectives To determine whether canakinumab is an effective and safe treatment in
PG.
Methods Five adult patients with clinically and histologically confirmed steroid-
refractory PG were enrolled in this prospective open-label study. They received
canakinumab 150 mg subcutaneously at week 0 with an optional 150 mg at
week 2 in case of an inadequate response [Physician’s Global Assessment (PGA)
≥ 2], and an optional 150–300 mg at week 8 depending on PGA. The primary
clinical end point was clinical improvement (PGA at least 1 from baseline)
and/or complete remission (PGA 0 or 1) at week 16. Real-time quantitative
polymerase chain reaction was performed on skin samples to quantify cytokine
mRNA levels.
Results Interleukin (IL)-1b and its known target genes IL6, CXCL8 and IL36A were
significantly increased in lesional skin of PG. Under canakinumab therapy, four
of five patients showed a decrease in target-lesion size, PGA and Dermatology
Life Quality Index (DLQI), and three of five achieved complete remission. The
mean diameter of target lesions decreased from 432  26 cm at visit 1 to
078  13 cm at visit 7 (P = 003). Mean DLQI decreased from 15  5 at
visit 1 to 8  4 by visit 7 (P = 001). Adverse effects were reported in two
patients: fatigue in one and worsening of disease at a nontarget lesion in the
other.
Conclusions Our data indicate that IL-1b plays a key pathogenic role in PG and
canakinumab may represent a therapeutic option for steroid-refractory PG.
What’s already known about this topic?
• Pyoderma gangrenosum is a rare, difficult-to-treat neutrophilic ulcerative skin dis-
ease frequently associated with systemic disease, and treatment can be challenging.
• The successful use of canakinumab in pyoderma gangrenosum has been reported
in the context of PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum and
acne), a recently characterized rare autosomal dominant autoinflammatory disease
of early onset.
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What does this study add?
• The proinflammatory cytokine interleukin (IL)-1b is abundant in its active form in
human pyoderma gangrenosum skin lesions.
• Blockade of IL-1b with the monoclonal antibody canakinumab can improve ster-
oid-resistant pyoderma gangrenosum.
• This provides novel evidence that IL-1b plays a role in the pathogenesis of pyo-
derma gangrenosum.
Pyoderma gangrenosum (PG) is a rare noninfectious neu-
trophilic dermatosis. It is characterized by sterile pustular skin
lesions that rapidly evolve into tender skin ulcers with under-
mined borders of varying size and depth, sometimes exposing
underlying tendons or muscles.1,2 PG is frequently associated
with systemic disease, most commonly inflammatory bowel
disease (65–93%), arthritis (16%) and lymphoproliferative
disorders (12%).3–6 The clinical course of PG can be mild,
aggressive, chronic or relapsing. Severe courses have been
reported, with multiple skin lesions, genital involvement and
extracutaneous manifestations including pulmonary involve-
ment.7–10
Only one prospective randomized controlled trial and a few
large case studies on PG have been reported to date.1,11–14
Treatment is usually directed towards inhibiting inflammation,
disease progression and pain. Systemic steroids are considered
the first-line therapy, although not all cases of PG are respon-
sive.15 Ciclosporin and tumour necrosis factor (TNF)-a inhibi-
tors have proved useful as second- and third-line therapies,
but resistance and worsening of disease have been
reported.15–17 Immunosuppressive mono- or polytherapy is
required in up to 71% of cases and has been associated with
persisting disease (mean 8 years) and a mortality of up to
23%.6,18–20 In responders to conventional therapy, on average
16 months were required to achieve remission.21
Overactivation of the innate immune system is assumed to
elicit PG, and high levels of interleukin (IL)-8 and TNF-a are
associated with the typical overwhelming neutrophilic infiltra-
tion found in PG.22 Interestingly, in PAPA syndrome (pyogenic
arthritis, pyoderma gangrenosum and acne)23,24 – a recently
characterized rare autosomal dominant autoinflammatory dis-
ease of early onset – and another PG-associated syndrome,25
mutations in proline–serine–threonine phosphatase-interacting
protein 1 (PSTPIP1/CD2BP1) were identified. These lead to acti-
vation of the cytosolic multimeric inflammasome protein com-
plex that promotes the maturation of the inflammatory
cytokines IL-1b and IL-18.
Transgenic mice carrying a mutation in the inflammasome
gene Nlrp3 (NLR familiy, pyrin domain containing 3) sponta-
neously develop neutrophil-rich skin lesions. This is equivalent
to the human mutation associated with the cryopyrin-associ-
ated periodic syndrome Muckle–Wells syndrome,26 which
involves increased IL-1b production. Intriguingly, an imbal-
ance in the adaptive immune system was recently shown with
polarization in favour of T helper (Th)1/Th17 cells and
downregulation of Th2 cells or a reduced regulatory T cell/
Th17 ratio.27,28 Overexpression of IL-1b and IL-8 in PG has
been reported previously,29 and the successful use of canaki-
numab in PG in the context of PAPA syndrome has been
reported.30–32 Therefore we considered that IL-1b may be
directly driving the development of PG and may be an attrac-
tive therapeutic target.
In this work we show that the proinflammatory cytokine
IL-1b is abundant in its active form in human PG skin lesions,
and that blockade of IL-1b with the monoclonal antibody
canakinumab can improve steroid-resistant PG, providing
novel evidence that IL-1b plays a role in the pathogenesis of
PG.
Materials and methods
Patients
Five adult patients (age > 18 years) with clinically and histo-
logically investigator-initiated confirmed PG were enrolled in
this prospective open-label study, having fulfilled the inclusion
criteria (Appendix S1; see Supporting Information) and pro-
vided their written informed consent. All five patients had
idiopathic PG without associated systemic disease, and had
failed one or more systemic therapy including systemic ster-
oids. The characteristics of these patients are shown in Table 1.
Their mean age was 523  195 years, and all patients
were white. The mean body weight was 873 kg and the
mean body mass index was 274  34 kg m2. The number
of PG lesions ranged from one to six with a mean of
28  18. The mean time between first symptoms and the
study start was 47  41 years.
Treatment
Canakinumab 150 mg was administered subcutaneously to all
patients at week 0, and a further 150 mg was administered
subcutaneously at week 2 in case of Physician’s Global Assess-
ment (PGA) > 2. At week 8 in case of PGA 0, canakinumab
150 mg was administered subcutaneously; in case of PGA 1–3
the cumulative dose of canakinumab administered so far (150
or 300 mg) was administered subcutaneously; in case of PGA
© 2015 The Authors. British Journal of Dermatology
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4 no further study drug was administered (Fig. S1; see Sup-
porting Information). The detailed study protocol is available
in Appendix S1.
At each visit during the treatment (weeks 0–8) and during
the follow-up period (weeks 9–16) physical examinations
were performed, including vital signs, examination of the tar-
get lesion, PGA, Dermatology Life Quality Index (DLQI) and
digital photographic documentation. At weeks 1, 8 and 16 a
complete blood count and measurements of C-reactive protein
and renal and liver function were performed. The surface area
and diameter of target lesions were calculated from digital
photographs – taken at the above study visits with a ruler next
to the lesion to enable a reference of scale – using digital cal-
culation software (Universal Desktop Ruler; AVPSoft, Voro-
nezh, Russia).
The primary clinical end point was induction of clinical
improvement by canakinumab (PGA score at least 1 from
baseline) and/or complete clinical remission (PGA 0 or 1) as
measured by PGA at week 16. Secondary end points were the
percentage of patients with complete clinical remission and
the percentage of patients with partial clinical improvement at
weeks 2, 4, 8 and 12; the change in target-lesion diameter
and area compared with baseline; and the quality of life mea-
sured by DLQI.
The study protocol (NCT01302795) was approved by the
clinical research ethics committee of Kanton Zurich (KEK-ZH-
Nr. 2010-0212/5) and Swissmedic.
Cytokine expression analysis
Real-time quantitative polymerase chain reaction
Formalin-fixed paraffin-embedded skin samples were deparaf-
finized, RNA was extracted, cDNA synthesized by reverse
transcription, and real-time quantitative polymerase chain
reaction (qPCR) performed with primers for IL-1a, IL-1b, IL-
6, CXCL8 (IL-8), IL-12b, IL-36a, IL36c, IFNc and TNF-a to
quantify tissue mRNA levels in patients with PG.
Interleukin-1b detection in skin-biopsy specimens
Formalin-fixed paraffin-embedded skin samples were sectioned
(5 lm), deparaffinized and immunostained with the use of
rabbit antihuman mature IL-1b (ab53175; Abcam, Cambridge,
Table 1 Characteristics of the patients with pyoderma gangrenosum (PG)
Patient number 1 2 3 4 5
Sex Male Male Male Male Female
Age at study
inclusion (years)
66 42 73 19 61
Duration of PG prior
to study inclusion (years)
41 40 124 02 27
Age at time of primary
manifestation of PG (years)
62 38 60 19 58
Body mass index (kg m2) 295 284 321 245 226
Target lesion Abdominal right Mammary left Abdominal right Right leg Inguinal left
Total lesion count 3 6 3 1 1
Prior treatments Systemic steroids,
dapsone
Systemic steroids,
ciclosporin A, etanercept,
infliximab,
cyclophosphamide,
intravenous
immunoglobulin
Systemic steroids,
ciclosporin A,
azathioprine,
mycophenolate mofetil,
etanercept,
cyclophosphamide,
dapsone
Systemic
steroids,
doxycycline
Systemic steroids,
ciclosporin A,
dapsone
Fig 1. Enhanced levels of interleukin (IL)-1b in lesional skin of patients with pyoderma gangrenosum (PG). (a) mRNA levels for the
proinflammatory cytokines IL-1a, IL-1b, IL-6, IL-8, IL-12, IL-36a, IL-36c, tumour necrosis factor (TNF)-a and interferon (IFN)-c in historical
lesional skin-biopsy samples from patients with PG (n = 7) and healthy human skin (n = 6) as assessed by quantitative polymerase chain reaction
(qPCR). (b) mRNA levels for IL-1b in historical lesional skin-biopsy samples of patients with PG (n = 7) compared with lesional skin-biopsy
samples of patients with eczema (n = 5) as assessed by qPCR. (c) Levels of IL-1b mRNA detected by qPCR in lesional skin samples of biopsied
patients with PG at the time of inclusion in the clinical trial (visit 1). Study patient 5 declined to have a skin biopsy at study inclusion (N.A.). (d)
IL-1b protein levels as detected by immunohistochemistry (anti-IL-1b, red staining) in a lesional skin biopsy taken from patient number 4 at the
time of study inclusion. For comparison, IL-1b immunostaining in a biopsy of severe eczema is shown. The haematoxylin and eosin stain (H&E)
of the lesional skin biopsy from patient 4 shows an abundant neutrophilic inflammatory infiltrate in the dermis. Sections incubated with an
unspecific antibody of the same isotype as the primary anti-IL-1b antibody (isotype) were included as a control for antibody specificity. (e)
Quantification of the intensity of IL-1b immunostaining within the epidermis and dermal inflammatory infiltrate (dermis) of healthy skin (n = 4),
eczema (n = 6) and PG (n = 7). Differences between groups were assessed using an unpaired Student’s t-test with subsequent Bonferroni
correction. n.s. (not significant) indicates a P-value > 005. *P ≤ 005, **P ≤ 001.
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U.K.) antibody or isotype control antibody (ab27478; Abcam)
in patients with PG.
To increase our sample numbers for real-time qPCR and
IL-1b detection, biopsies from historical cases of PG were
analysed, in addition to biopsies from patients with the
inflammatory disease eczema and control biopsies from
healthy individuals. Further details are provided in Appendix
S2 (see Supporting Information).
For statistical analysis a t-test with subsequent Bonferroni
correction was performed.
Results
Inflammatory cytokine expression
Gene expression analysis of selected proinflammatory cytoki-
nes, assessed in historical lesional skin biopsies of patients
with PG, showed significantly increased expression of the
genes encoding IL-1a, IL-1b, IL-6, IL-8 and IL-36a when
compared with skin of healthy controls (Fig. 1a). Expression
levels of TNF-a, interferon-c, IL-36c and IL-12 were not sig-
nificantly increased. Levels of IL-1b mRNA in PG lesions
from historical cases were also significantly increased when
compared with levels observed in patients with eczema
(Fig. 1b). In all steroid-resistant patients with PG selected for
this clinical trial who consented to a skin biopsy, analysis of
IL-1b mRNA levels in lesional skin performed upon screening
also revealed high levels of IL-1b (Fig. 1c). In these five
patients, as well as in a retrospective series of seven lesional
skin biopsies from patients with PG, semiquantitative evalua-
tion by immunohistochemistry indicated that IL-1b was sig-
nificantly more abundant at the protein level in the
epidermal and dermal compartments of skin lesions from
patients with PG than in patients with eczema and healthy
controls (Fig. 1d, e).
Response to canakinumab
All patients received canakinumab 150 mg subcutaneously at
week 0 and at week 2, and patients 3–5 also received 300 mg
subcutaneously at week 8, as their PGA was between 1 and 3.
Patient 1 did not get another injection of canakinumab accord-
ing to protocol as the PGA was 4, and patient 2 dropped out
at week 8. The response of each of the five patients to treat-
ment with canakinumab is shown in Figure 2.
The primary clinical end point was induction of clinical
improvement with canakinumab (PGA score at least 1 from
baseline) and/or complete clinical remission (PGA 0 or 1) as
measured by PGA at week 16. Three of the five patients
(60%, patients 1, 3 and 4) showed complete resolution of
clinical signs of inflammation and complete healing of the
target lesion at week 16, and one patient (20%, patient 2 at
visit 4 before dropout) had a PGA score improvement of 2
(Fig. 2a).
Secondary end points were the percentage of patients with
complete clinical remission and the percentage of patients
with partial clinical improvement at weeks 2, 4, 8 and 12;
the change in target-lesion diameter and area compared with
baseline; and the quality of life measured by DLQI. Three of
five patients (60%) showed complete healing with a decrease
of PG target-lesion diameter and area to zero, whereas one
of the five patients (20%) showed a reduction in PG target-
lesion area but not diameter (patient 2). Four of five patients
showed a reduction in DLQI between study visits 1 and 7
(Fig. 2a).
The mean diameter of all five patients’ target lesions signifi-
cantly decreased, from 432  26 cm at visit 1 to
078  13 cm at visit 7 (P = 003, Fig. 2b). The mean area
of all five patients’ target lesions also decreased – but without
reaching significance – from 91  95 cm2 at visit 1 to
03  05 cm2 at visit 7 (P = 009, Fig. 2b). Assessment of
the DLQI showed a significant mean decrease from 15  5 at
visit 1 to 8  4 at visit 7 (P = 001, Fig. 2b).
Taken together, at 16 weeks after canakinumab initiation,
four of five patients (80%) had reached the primary clinical
end point of clinical improvement (PGA score at least 1
from baseline), and complete clinical remission (PGA 0 or 1)
was achieved in three patients (60%). The clinical course of
patient 4 is shown in Figure 2c and that of the other patients
in Figure S2 (see Supporting Information).
Adverse effects were reported in two of the five patients
(40%). One patient reported fatigue after receiving canakinu-
mab, without any other objective clinical or laboratory
anomalies. The second patient (patient number 2), a 42-year-
old man with a 6-year history of chronic relapsing PG previ-
ously treated with numerous immunosuppressive regimens
(Table 1), suddenly developed three new small scrotal ulcers
after study visit 4. He was hospitalized abroad on suspicion of
rapidly progressive infectious genital ulcers during immuno-
suppression, leading to registration of a serious adverse event
(SAE) and dropout from the study. However, the target lesion
of this patient that had improved already by the time of the
SAE had healed completely by week 16 and did not relapse.
Clinical work-up after hospital admission eventually ruled out
infectious skin disease, thus suggesting a relapse of PG at a
distant location under canakinumab treatment in this patient.
No patient was on concomitant systemic therapy during the
study.
Fig 2. Clinical response of pyoderma gangrenosum (PG) to canakinumab therapy. (a) Target-lesion diameter (PG diameter), target-lesion area (PG
area), Physician’s Global Assessment (PGA) score and Dermatology Life Quality Index (DLQI) as recorded in study patients 1–5 at study visits 1
(week 1), 2 (week 0), 3 (week 2), 4 (week 4), 5 (week 8), 6 (week 12) and 7 (week 16) are depicted graphically for each study patient
separately. (b) The evolution of the mean target-lesion diameter (PG diameter), target-lesion area (PG area), PGA score and DLQI for study
patients 1–5 between study visits 1 and 7. Mean values are shown with SEM. (c) Photographic illustration of the target lesion of study patient 4 at
visits 1, 3 and 7.
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(a) PG Area PGA Score DLQIPG Diameter
Pat 1
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Pat 3
Pat 4
(b)
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Pat 5
Visit 1 Visit 3 Visit 7
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Pat 1-5
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Discussion
The management of PG unresponsive to conventional immuno-
suppressive therapy is challenging.33 Although systemic ster-
oids with or without associated ciclosporin are widely
considered to be the first-line therapy, cases unresponsive to
this regimen are common. Little evidence exists from clinical
studies concerning the frequency of severe steroid-resistant PG,
the mortality associated with PG or the optimal therapeutic
regimen for steroid-resistant PG. The most comprehensive anal-
ysis published to date is a retrospective chart review performed
between 2000 and 2007 on patient data from the Research
Patient Data Repository of the Brigham and Women’s Hospital
and Massachusetts General Hospital.3 In that study 103 patients
with PG were analysed by the most frequently reported multi-
modal therapy regimen, and the mortality during the 8-year
study period was 16%.
Saracino et al.34 reported the therapy and outcome of 26
cases of PG requiring inpatient management. In their case ser-
ies, prednisolone then ciclosporin were the most commonly
prescribed systemic therapies, with 50% of patients showing
complete ulcer healing at the 6-month follow-up, and a
reported mortality of 27%.34 The only randomized controlled
study published to date compared infliximab with placebo,
showing significant clinical improvement in 46% of patients
(six of 13) at week 2 in the infliximab group compared with
6% (one of 17) in the placebo group.13 Overall 69% of
patients (20 of 29) demonstrated a beneficial clinical response
to infliximab after 6 weeks, and 31% of patients failed to
respond. These studies highlight the severity of PG, the need
for aggressive therapy and the high overall morbidity and
mortality of the disease.
Canakinumab is a human monoclonal antibody that selec-
tively blocks IL-1b and has no known cross-reactivity with
other IL-1 family members.35 Canakinumab is approved for
the treatment of cryopyrin-associated periodic syndromes, a
group of monogenic autoinflammatory syndromes including
familial cold autoinflammatory syndrome, Muckle–Wells syn-
drome and neonatal-onset multisystem inflammatory disease,
which are characterized by mutations in the NLRP3 gene lead-
ing to overproduction of IL-1b and systemic inflammation.36
Recently, clinical reports have suggested a therapeutic effect of
drugs targeting IL-1 signalling in patients with complex auto-
inflammatory syndromes involving PG as a clinical element,
namely in PAPA and PASH syndrome (pyoderma, acne and
suppurative hidradenitis).30,37,38
Our data show that idiopathic PG is characterized by over-
production of IL-1b, as demonstrated by increased IL-1b
mRNA and protein within skin lesions of PG when compared
with eczematous skin and healthy controls. Using canakinu-
mab, we successfully induced complete (60% of patients) or
partial (20% of patients) remission in patients with steroid-
refractory PG within the 16-week study period. This study
was not limited to patients in the inflammatory phase, as
patient 5 had a chronic crusted lesion with a plasma-cell-rich
inflammatory border. In sharp contrast to the other patients,
no response was observed in this patient.
Although PG impairs the quality of life of patients, this
parameter has rarely been specifically analysed.39 In our
patients, who had a mean DLQI of 15 indicative of a severe
impairment in their quality of life at study initiation, the DLQI
decreased significantly to a mean of 8 upon treatment with
canakinumab.
Limitations of this study are the small sample size and the
open-label study design. Also, clinical scores used for the evalu-
ation of efficacy are known to be susceptible to inter- and
intrarater variations. However, in an effort to minimize this lim-
itation we applied a software-based analysis of the ulcer size
(surface area and diameter) using standardized digital pho-
tographs of the target lesion taken at each study visit.40 Another
limitation is that the planned analysis of histological parameters
– such as neutrophil and lymphocyte numbers in the responder,
partial responder and nonresponder patients at week 16 com-
pared with baseline – could not be performed, as most patients
refused a biopsy at week 16 in fear of a possible pathergy phe-
nomenon and relapse/flare of their PG (patient 5 declined a
biopsy at study inclusion but had a histologically proven PG).
Taken together, our investigator-initiated study suggests that
despite the above limitations, canakinumab may be an effec-
tive and well-tolerated treatment for idiopathic, steroid-refrac-
tory PG. Our clinical and biological data indicate that the
proinflammatory cytokine IL-1b very likely plays a key patho-
genic role in PG and offers a rationale for further clinical trials
evaluating canakinumab or IL-1b-blocking agents for the treat-
ment of PG.
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